Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03201965




Registration number
NCT03201965
Ethics application status
Date submitted
27/06/2017
Date registered
28/06/2017
Date last updated
15/08/2024

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Scientific title
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
Secondary ID [1] 0 0
2016-001737-27
Secondary ID [2] 0 0
CR108193
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Amyloidosis 0 0
Condition category
Condition code
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Bortezomib
Treatment: Drugs - Dexamethasone, 40 mg
Treatment: Drugs - Daratumumab

Active comparator: CyBorD alone (cyclophosphamide/bortezomib/dexamethasone) - Participants will receive dexamethasone (40 milligrams \[mg\] orally or intravenous \[IV\] dose), followed by cyclophosphamide (300 milligram per meter square \[mg/m\^2\] orally or IV dose), then bortezomib (1.3 mg/m\^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.

Experimental: CyBorD plus Daratumumab - Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m\^2 orally or IV dose weekly) and bortezomib (1.3 mg/m\^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.


Treatment: Drugs: Cyclophosphamide
Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.

Treatment: Drugs: Bortezomib
Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.

Treatment: Drugs: Dexamethasone, 40 mg
Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.

Treatment: Drugs: Daratumumab
Participants will receive 1800 mg of daratumumab subcutaneously.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Overall Complete Hematologic Response (CHR)
Timepoint [1] 0 0
Up to 2.4 years

Eligibility
Key inclusion criteria
* Histopathological diagnosis of amyloidosis based on detection by immunohistochemistry and polarizing light microscopy of green bi-refringent material in congo red stained tissue specimens (in an organ other than bone marrow) or characteristic electron microscopy appearance
* Measurable disease of amyloid light-chain (AL) amyloidosis as defined by at least one of the following:

1. serum monoclonal (M)-protein greater than or equal (>=) 0.5 grams/deciliter (g/dL) by protein electrophoresis (routine serum protein electrophoresis and immunofixation [IFE] performed at a central laboratory)
2. serum free light chain greater than or equal to (>=) 50 milligram/Liter (mg/L) with an abnormal kappa:lambda ratio or the difference between involved and uninvolved free light chains (dFLC) >= 50 mg/L
* One or more organs impacted by AL amyloidosis according to consensus guidelines
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior therapy for AL amyloidosis or multiple myeloma including medications that target CD38, with the exception of 160 mg dexamethasone (or equivalent corticosteroid) maximum exposure prior to randomization
* Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, >= 60 percent (%) plasma cells in the bone marrow, or hypercalcemia
* Evidence of significant cardiovascular conditions as specified below:

1. NT-ProBNP > 8500 nanogram per liter (ng/L)
2. New York Heart Association (NYHA) classification IIIB or IV heart failure
3. Heart failure that in the opinion of the investigator is on the basis of ischemic heart disease (eg, prior myocardial infarction with documented history of cardiac enzyme elevation and electrocardiogram [ECG] changes) or uncorrected valvular disease and not primarily due to AL amyloid cardiomyopathy
4. Inpatient admission to a hospital for unstable angina or myocardial infarction within the last 6 months prior to first dose or percutaneous cardiac intervention with recent stent within 6 months or coronary artery bypass grafting within 6 months
5. For participants with congestive heart failure, cardiovascular-related hospitalizations within 4 weeks prior to randomization
6. Participants with a history of sustained ventricular tachycardia or aborted ventricular fibrillation or with a history of atrioventricular (AV) nodal or sinoatrial (SA) nodal dysfunction for which a pacemaker/implantable cardioverter-defibrillators [ICD] is indicated but not placed (participants who do have a pacemaker/ICD are allowed on study)
7. Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) > 500 milliseconds (msec). Participants who have a pacemaker may be included regardless of calculated QTc interval
8. Supine systolic blood pressure < 90 millimeter of mercury (mmHg), or symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure upon standing of > 20 mmHg despite medical management (eg, midodrine, fludrocortisones) in the absence of volume depletion
* Planned stem cell transplant during the first 6 cycles of protocol therapy are excluded. Stem cell collection during the first 6 cycles of protocol therapy is permitted
* Known to be seropositive for human immunodeficiency virus (HIV)
* Any one of the following:

1. Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]). Participants with resolved infection (ie, participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded
2. Known to be seropositive for hepatitis C (except in the setting of a sustained virologic response [SVR], defined as aviremia at least 12 weeks after completion of antiviral therapy)
* Grade 2 sensory or Grade 1 painful peripheral neuropathy

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/10/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
16/08/2024
Actual
Sample size
Target
Accrual to date
Final
416
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [2] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [3] 0 0
Westmead Hospital - Westmead
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 0 0
3128 - Box Hill
Recruitment postcode(s) [2] 0 0
6009 - Nedlands
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Maryland
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Michigan
Country [9] 0 0
United States of America
State/province [9] 0 0
Minnesota
Country [10] 0 0
United States of America
State/province [10] 0 0
Missouri
Country [11] 0 0
United States of America
State/province [11] 0 0
New York
Country [12] 0 0
United States of America
State/province [12] 0 0
North Carolina
Country [13] 0 0
United States of America
State/province [13] 0 0
Ohio
Country [14] 0 0
United States of America
State/province [14] 0 0
Oregon
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Utah
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Belgium
State/province [20] 0 0
Anderlecht
Country [21] 0 0
Belgium
State/province [21] 0 0
Gent
Country [22] 0 0
Belgium
State/province [22] 0 0
Kortrijk
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Brazil
State/province [24] 0 0
Porto Alegre
Country [25] 0 0
Brazil
State/province [25] 0 0
Recife
Country [26] 0 0
Brazil
State/province [26] 0 0
Rio de Janeiro
Country [27] 0 0
Brazil
State/province [27] 0 0
Salvador
Country [28] 0 0
Brazil
State/province [28] 0 0
Sao Jose do Rio Preto
Country [29] 0 0
Brazil
State/province [29] 0 0
Sao Paulo
Country [30] 0 0
Brazil
State/province [30] 0 0
São Paulo
Country [31] 0 0
Canada
State/province [31] 0 0
Alberta
Country [32] 0 0
Canada
State/province [32] 0 0
British Columbia
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
Canada
State/province [34] 0 0
Quebec
Country [35] 0 0
China
State/province [35] 0 0
Beijing
Country [36] 0 0
China
State/province [36] 0 0
Hangzhou
Country [37] 0 0
China
State/province [37] 0 0
Shanghai
Country [38] 0 0
China
State/province [38] 0 0
Wenzhou
Country [39] 0 0
Denmark
State/province [39] 0 0
Aarhus C
Country [40] 0 0
Denmark
State/province [40] 0 0
Copenhagen
Country [41] 0 0
Denmark
State/province [41] 0 0
Odense
Country [42] 0 0
France
State/province [42] 0 0
Dijon
Country [43] 0 0
France
State/province [43] 0 0
Lille cedex
Country [44] 0 0
France
State/province [44] 0 0
Limoges
Country [45] 0 0
France
State/province [45] 0 0
Marseille
Country [46] 0 0
France
State/province [46] 0 0
Nantes cedex 01
Country [47] 0 0
France
State/province [47] 0 0
PARIS cedex 10
Country [48] 0 0
France
State/province [48] 0 0
Pierre - Bénite cedex
Country [49] 0 0
France
State/province [49] 0 0
Poitiers
Country [50] 0 0
France
State/province [50] 0 0
Toulouse
Country [51] 0 0
France
State/province [51] 0 0
Tours cedex
Country [52] 0 0
France
State/province [52] 0 0
Vandoeuvre les Nancy
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Düsseldorf
Country [55] 0 0
Germany
State/province [55] 0 0
Essen
Country [56] 0 0
Germany
State/province [56] 0 0
Hamburg
Country [57] 0 0
Germany
State/province [57] 0 0
Heidelberg
Country [58] 0 0
Germany
State/province [58] 0 0
Tübingen
Country [59] 0 0
Germany
State/province [59] 0 0
Würzburg
Country [60] 0 0
Greece
State/province [60] 0 0
Athens
Country [61] 0 0
Greece
State/province [61] 0 0
Patra
Country [62] 0 0
Hungary
State/province [62] 0 0
Budapest
Country [63] 0 0
Israel
State/province [63] 0 0
Haifa
Country [64] 0 0
Israel
State/province [64] 0 0
Jerusalem
Country [65] 0 0
Israel
State/province [65] 0 0
Ramat-Gan
Country [66] 0 0
Israel
State/province [66] 0 0
Tel-Aviv
Country [67] 0 0
Israel
State/province [67] 0 0
Zerifin
Country [68] 0 0
Italy
State/province [68] 0 0
Bari
Country [69] 0 0
Italy
State/province [69] 0 0
Bologna
Country [70] 0 0
Italy
State/province [70] 0 0
Palermo
Country [71] 0 0
Italy
State/province [71] 0 0
Pavia
Country [72] 0 0
Italy
State/province [72] 0 0
Roma
Country [73] 0 0
Italy
State/province [73] 0 0
Torino
Country [74] 0 0
Japan
State/province [74] 0 0
Fukushima
Country [75] 0 0
Japan
State/province [75] 0 0
Hiroshima
Country [76] 0 0
Japan
State/province [76] 0 0
Hokkaido
Country [77] 0 0
Japan
State/province [77] 0 0
Kanazawa
Country [78] 0 0
Japan
State/province [78] 0 0
Kumamoto-City
Country [79] 0 0
Japan
State/province [79] 0 0
Kyoto
Country [80] 0 0
Japan
State/province [80] 0 0
Matsumoto
Country [81] 0 0
Japan
State/province [81] 0 0
Matsuyama
Country [82] 0 0
Japan
State/province [82] 0 0
Nagoya
Country [83] 0 0
Japan
State/province [83] 0 0
Okayama
Country [84] 0 0
Japan
State/province [84] 0 0
Shibuya
Country [85] 0 0
Japan
State/province [85] 0 0
Tokushima
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Busan
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Seoul
Country [88] 0 0
Mexico
State/province [88] 0 0
Guadalajara
Country [89] 0 0
Mexico
State/province [89] 0 0
Monterrey
Country [90] 0 0
Netherlands
State/province [90] 0 0
Den Haag
Country [91] 0 0
Netherlands
State/province [91] 0 0
Groningen
Country [92] 0 0
Netherlands
State/province [92] 0 0
Rotterdam
Country [93] 0 0
Netherlands
State/province [93] 0 0
Utrecht
Country [94] 0 0
Netherlands
State/province [94] 0 0
Veldhoven
Country [95] 0 0
Poland
State/province [95] 0 0
Chorzów
Country [96] 0 0
Poland
State/province [96] 0 0
Poznan
Country [97] 0 0
Poland
State/province [97] 0 0
Warszawa
Country [98] 0 0
Spain
State/province [98] 0 0
Badalona
Country [99] 0 0
Spain
State/province [99] 0 0
Barcelona
Country [100] 0 0
Spain
State/province [100] 0 0
Madrid
Country [101] 0 0
Spain
State/province [101] 0 0
Pamplona
Country [102] 0 0
Spain
State/province [102] 0 0
Salamanca
Country [103] 0 0
Spain
State/province [103] 0 0
San Cristóbal de La Laguna
Country [104] 0 0
Spain
State/province [104] 0 0
Valencia
Country [105] 0 0
Sweden
State/province [105] 0 0
Boras
Country [106] 0 0
Sweden
State/province [106] 0 0
Lund
Country [107] 0 0
Turkey
State/province [107] 0 0
Ankara
Country [108] 0 0
Turkey
State/province [108] 0 0
Antalya
Country [109] 0 0
Turkey
State/province [109] 0 0
Atakum
Country [110] 0 0
Turkey
State/province [110] 0 0
Istanbul
Country [111] 0 0
Turkey
State/province [111] 0 0
Izmir
Country [112] 0 0
Turkey
State/province [112] 0 0
Talas
Country [113] 0 0
United Kingdom
State/province [113] 0 0
Birmingham
Country [114] 0 0
United Kingdom
State/province [114] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT03201965